FDA Approves Postpartum Depression Drug That Works Within Days

  • 📰 ADDitudeMag
  • ⏱ Reading Time:
  • 23 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 61%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

A once-daily medication taken for only 14 days was deemed safe and effective in the treatment of postpartum depression, which impacts a third of women with ADHD, according to an ADDitude survey.

, typically take four to six weeks to reach full effect, and are often taken indefinitely. When the first drug specifically created to treat postpartum depression, brexanolone, was approved in 2019, it marked a breakthrough in the treatment of the condition. However, because brexanolone can only be administered via an intravenous drip, requiring a costly two-day stay in a healthcare facility, it has not been widely used.

Brexanolone and zuranolone were both developed by Biogen and Sage Pharmaceuticals and work in much the same way. Both medications modulate levels of allopregnanolone, a neuro-active steroid that is made in the body from theNow that zuranolone has been approved by the FDA, the U.S. Drug Enforcement Administration must complete a review over the next 90 days, during which it will assign a schedule to the medication, which is a controlled substance.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 311. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

US FDA approves Pfizer's blood cancer therapyThe U.S. Food and Drug Administration on Monday granted accelerated approval to Pfizer's therapy for treating patients with a type of blood cancer that is difficult to treat, the company said.
Source: Reuters - 🏆 2. / 97 Read more »